← Chemomab Therapeutics Ltd.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Revenue | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Cost of Goods and Services Sold | — | — | — | — | $3.3m |
$5.1m
+55.35%
|
$4.4m
-14.57%
|
$2.5m
-43.89%
|
$2.3m
-5.64%
|
— | |
| Gross Profit | — | — | — | — | — | ($5.1m) |
($4.4m)
+14.57%
|
($2.5m)
+43.89%
|
($2.3m)
+5.64%
|
— | |
| Research And Development | $6.2m | $7.6m | $13.3m | $3.8m | $6.3m | $17.0m | $18.4m | $11.3m | $5.8m | $4.3m | |
| General and administrative | $3.2m | $5.5m | $6.2m | $7.2m | $6.0m | $11.6m | $7.1m | $3.4m | $3.7m | $3.7m | |
| Other General and Administrative Expense | — | — | — | — | $216k | $1.4m | $323k | $124k | $142k | — | |
| Operating Lease, Expense | — | — | — | $242k | — | — | — | — | — | — | |
| Operating Expenses | — | — | $22.9m | $11.7m | $12.4m | $28.5m | $25.5m | $14.7m | $9.6m | $7.9m | |
| Operating Income (Loss) | ($9.4m) |
($13.0m)
-38.88%
|
$27.1m
+307.94%
|
$11.6m
-57.20%
|
$12.5m
+7.49%
|
($28.5m)
-328.67%
|
($25.5m)
+10.77%
|
($103.0m)
-304.57%
|
($112.0m)
-8.74%
|
($7.9m)
+92.92%
|
|
| Interest Income | — | — | — | — | — | $353k | $1.2m | $794k | $572k | $572k | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | ($40k) | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | $9.0m | ($7.4m) | |
| Loss before income taxes | — | — | — | — | $12.5m | $28.2m | $24.2m | $13.9m | $9.0m | — | |
| Pre-Tax Income | — | — | $27.1m | $11.6m | $12.5m | ($28.2m) | ($24.2m) | ($13.9m) | ($9.0m) | ($7.4m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | $27.1m | $11.6m | $12.5m | ($28.2m) | ($24.2m) | ($13.9m) | ($9.0m) | ($7.4m) | |
| Income Tax Expense Continuing Operations | $323k | $621k | — | — | — | — | — | — | — | $0 | |
| Income Tax expenses | — | — | — | $0 | $0 | ($534k) | $0 | $0 | $0 | $0 | |
| Net loss for the year | — | — | — | — | $12.5m | $27.6m | $24.2m | $13.9m | $9.0m | — | |
| Net Income From Continuing And Discontinued Operation | — | — | ($27.1m) | ($11.6m) | ($12.5m) | ($27.6m) | ($24.2m) | ($13.9m) | ($9.0m) | ($7.4m) | |
| Income (Loss) from Continuing Operations, Per Basic Share | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | |
| Earnings Per Share, Basic | — | — | — | — | $0.06 | $0.12 | $0.10 | $0.04 | $0.02 | ($1.12) | |
| Earnings Per Share, Diluted | — | — | — | — | $0.06 | $0.12 | $0.10 | $0.04 | $0.02 | ($1.12) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | 207.5m | 227.6m | 235.0m | 359.0m | 510.2m | 6.9m | |
| Weighted average number of Ordinary Shares outstanding, basic | — | — | — | — | 207.5m | 227.6m | 235.0m | 359.0m | 510.2m | — | |
| Weighted average number of Ordinary Shares outstanding, diluted | — | — | — | — | 207.5m | 227.6m | 235.0m | 359.0m | 510.2m | — | |
| Basic Average Shares | — | — | — | — | — | $2.8m | $2.9m | $4.1m | $6.4m | $6.9m | |
| Diluted Average Shares | — | — | — | — | — | $2.8m | $2.9m | $4.1m | $6.4m | $6.9m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | 207.5m | 227.6m | 235.0m | 359.0m | 510.2m | 6.9m | |
| Additional Financial Items | |||||||||||
| Applicable Tax Rate | $0 | $0 | — | — | — | — | — | — | — | — | |
| Finance Income | $1k | $1.1m | — | — | — | — | — | — | — | — | |
| Profit Loss Before Tax | ($9.5m) | ($12.7m) | — | — | — | — | — | — | — | — | |
| Profit Loss From Operating Activities | ($9.4m) | ($13.0m) | — | — | — | — | — | — | — | — | |
| Financing income, net | — | — | — | — | $111k | ($353k) | ($1.2m) | ($794k) | ($572k) | — | |
| Diluted EPS | — | — | — | — | — | ($9.68) | ($8.24) | ($3.44) | ($1.44) | ($1.12) | |
| Diluted NI Availto Com Stockholders | — | — | ($27.1m) | ($11.6m) | ($12.5m) | ($27.6m) | ($24.2m) | ($13.9m) | ($9.0m) | ($7.4m) | |
| Insurance And Claims | — | — | — | — | — | $1.1m | $648k | $538k | $499k | $499k | |
| Normalized EBITDA | — | — | — | — | — | ($28.5m) | ($25.4m) | ($14.7m) | ($9.5m) | ($7.9m) | |
| Normalized Income | — | — | ($27.1m) | ($11.6m) | ($12.5m) | ($27.6m) | ($24.2m) | ($13.9m) | ($9.0m) | ($7.4m) | |
| Other Gand A | — | — | — | — | — | $4.0m | $2.5m | $1.2m | $1.4m | — | |
| Reconciled Depreciation | — | — | — | — | — | $58k | $67k | $53k | $70k | $70k | |
| Rent And Landing Fees | — | — | — | — | — | $24k | $81k | $50k | $60k | $60k | |
| Salaries And Wages | — | — | — | — | — | $6.4m | $3.9m | $1.6m | $1.8m | $1.8m | |
| Selling General And Administration | $3.2m | $5.5m | $6.2m | $7.2m | $6.0m | $11.6m | $7.1m | $3.4m | $3.7m | — | |
| Tax Effect Of Unusual Items | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Tax Provision | — | — | — | $0 | $0 | ($534k) | $0 | $0 | $0 | $0 | |
| Tax Rate For Calcs | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Expense From Share-Based Payment Transactions With Employees | $700k | $1.9m | — | — | — | — | — | — | — | — | |
| Finance Costs | $92k | $741k | — | — | — | — | — | — | — | — | |
| Rent Expense Supplemental | — | — | — | — | — | $24k | $81k | $50k | $60k | $60k | |
| Net Foreign Exchange Loss | $87k | $170k | — | — | — | — | — | — | — | — | |
| Total Expenses | — | — | $22.9m | $11.7m | $12.4m | $28.5m | $25.5m | $14.7m | $9.6m | $7.9m | |
| Total Other Finance Cost | — | — | — | — | $111k | ($353k) | ($1.2m) | ($794k) | ($572k) | ($572k) |